Slide 1: Roche logo
Slide 2: Roche HY 2020 results
Roche HY 2020 results Basel, 23 July 2020
Slide 3: Forward-looking statements
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, str
Slide 4: Group
Group Severin Schwan Chief Executive Officer
Slide 5: HY 2020 performance, Outlook
HY 2020 performance Outlook 5
Slide 6: Significant COVID-19 impact
Significant COVID-19 impact Pharmaceuticals • Significant decline in May due to delay of HCP visits, recovering since June • Launch of NMEs, readouts & pivotal trial starts largely on track • Continued good growth momentum of new products (+37%), offsetting biosimilar erosion Diagnostics • Increase
Slide 7: HY 2020: Sales growth despite COVID-19
HY 2020: Sales growth despite COVID-19 HY 2020 HY 2019 Change in % CHFbn CHFbn CHF CER Pharmaceuticals Division 23.2 24.2 -4 1 Diagnostics Division 6.1 6.3 -3 3 Roche Group 29.3 30.5 -4 1 CER=Constant Exchange Rates 7
Slide 8: Q2 2020: Heavily impacted by COVID-19
Q2 2020: Heavily impacted by COVID-19 16% 14% 13% 12% 10% 9% 9% 8% 8% 7% 7% 7%7% 7% 6% 6%6% 6% 6% 6% 6% 6% 8% 6% 6% 6% 5% 4% 5% 5% 5% 4% 2% 4% 4% 4% 4% 4% 3% 3% 2% 0% -2% -4% -4% -6% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 12 12 12 12 13
Slide 9: HY 2020: Group sales - May heavily impacted by COVID-19
HY 2020: Group sales - May heavily impacted by COVID-19 Recovery started in June Pharmaceuticals • Impact in May driven by patients delaying appointments (mainly but not only chronic diseases) • Recovery in the last weeks of the quarter Diagnostics • Impact in April/May driven by decline in routine
Slide 10: Good sales growth in International and Europe
HY 2020: Good sales growth in International and Europe New products with strong momentum -2% +14% CHFbn CER growth CHFm Diagnostics Pharma -4% nal US HY values reported in CHFm and variances in CERm; 1 Erivedge, Perjeta, Kadcyla, Gazyva, Esbriet, Cotellic, Alecensa, Tecentriq, Ocrevus, Hemlibra, Xof
Slide 11: New products with strong momentum
New products with strong momentum – accelerated rejuvenation CHFm % of Pharma Sales Pharma sales mix 12,000 HY 2019 10,500 38% 28% 9,000 42% 7,500 28% 30% 6,000 20% HY 2020 4,500 14% 3,000 32% 38% 1,500 0 HY 2017 HY 2018 HY 2019 HY 2020 30% Erivedge Perjeta Kadcyla Gazyva Esbriet New products launch
Slide 12: Roche significantly advancing patient care
Roche significantly advancing patient care Pivotal trials on track despite difficult environment Pivotal trial recruitment finished in HY1 2020 ipatasertib 1L TNBC (Ph III: IPATunity130) risdiplam SMA type 1/2/3 (Ph II: JEWELFISH) gantenerumab Alzheimer’s disease (Ph III: GRADUATE 1 & 2) tominersen
Slide 13: Core OP and Core EPS maintained at high levels
HY 2020: Core OP and Core EPS maintained at high levels Core operating profit Core EPS Operating free cash flow 40.6% 40.2% 28.6% % of sales 39.7% 24.6% 17.2% CHFbn +2% at CER CHF +2% at CER CHFbn -26% at CER 11.12 12.4 10.44 11.8 8.0 7.5 5.0 9.84 11.2 HY 2018 HY 2019 HY 2020 HY 2018 HY 2019 HY 2020
Slide 14: HY 2020 performance, Outlook
HY 2020 performance Outlook 14
Slide 15: Major pipeline advances and upcoming launches in HY2 2020
Major pipeline advances and upcoming launches in HY2 2020 Pharma Diagnostics 3 Upcoming NME launches 4 Upcoming key launches • risdiplam in SMA • cobas® SARS-CoV-2 & Influenza A/B for use on the • Enspryng (satralizumab) in NMOSD cobas® Liat® System • pralsetinib* in RET+ NSCLC; Thyroid cancer • cob
Slide 16: 2020 outlook confirmed
2020 outlook confirmed Further growing top and bottom line Group sales growth1 • Low- to mid-single digit Core EPS growth1 • Broadly in line with sales growth Dividend outlook • Further increase dividend in Swiss francs 1 At Constant Exchange Rates (CER); based on the current assessment of the COVID
Slide 17: Pharmaceuticals Division
Pharmaceuticals Division Bill Anderson CEO Roche Pharmaceuticals
Slide 18: Replace and extend the business: Further milestones achieved
Replace and extend the business: Further milestones achieved Entering new Replace/extend existing businesses Achievements Q2 2020 franchises Oncology: Entering new franchises Gazyva, Tecentriq (mUC, TNBC, Tecentriq: US approval in 1L HCC (with Avastin) Venclexta, SCLC, HCC, mM), ipatasertib: Positiv
Slide 19: COVID-19 impact in May, but recovery starting in June
COVID-19 impact in May, but recovery starting in June • Broad COVID-19 impact due to missed patient visits and postponed new patient starts (e.g. breast cancer franchise, hematology franchise, neuroscience franchise) • Immunology franchise holds up well with strong adherence to therapy by patients w
Slide 20: Pharmaceuticals Division sales
HY 2020: Pharmaceuticals Division sales Growth in International and Europe HY 2020 HY 2019 Change in % CHFm CHFm CHF CER Pharmaceuticals Division 23,202 24,194 -4 1 United States 12,464 13,370 -7 -4 Europe 4,190 4,221 -1 5 Japan 1,908 1,988 -4 -2 International 4,640 4,615 1 11 CER=Constant Exchange
Slide 21: Pharma profitability maintained at high level
HY 2020: Pharma profitability maintained at high level 2020 CER growth CHFm abs. CER vs PY Sales 23,202 +193 1% Royalties & other op. inc. 1,070 -150 -12% Cost of sales -4,175 +620 -13% M&D -3,266 -7 0% R&D -5,077 -358 7% G&A -793 -79 11% Core operating profit 10,961 +220 2% Core OP in % of sales 47
Slide 22: New medicines compensating for biosimilar erosion
HY 2020: New medicines compensating for biosimilar erosion Tecentriq +74% Hemlibra +94% Ocrevus +25% Actemra / RoActemra +36% Perjeta +17% Kadcyla +39% Alecensa +34% Gazyva +35% Polivy >500% Esbriet +11% TNKase / Activase +4% Xofluza +357% Xolair +2% Lucentis -19% US Avastin -18% Europe MabThera -23
Slide 23: Oncology sales -6% with COVID-19 impact in May
HY 2020: Oncology sales -6% with COVID-19 impact in May YoY CER growth Perjeta (+17%) HER2 franchise Herceptin -7% HER2 franchise Kadcyla (+39%) • Kadcyla and Perjeta with strong global uptake in adjuvant BC Avastin Avastin -18% Avastin franchise Polivy (>500%) Hematology -15% • Biosimilar erosion i
Slide 24: HER2 franchise: Growth for Perjeta and Kadcyla
HER2 franchise: Growth for Perjeta and Kadcyla, Phesgo approved CHFm YoY CER growth 4,000 HER2 franchise Q2 update 3,500 • COVID-19 impact due to lower BC screening rates • Perjeta (+12%): Global growth driven by eBC (APHINITY) and 3,000 +8% +3% early uptake in China +7% 2,500 -12% • Kadcyla (+26%):
Slide 25: HER2 franchise: Phesgo US approval
HER2 franchise: Phesgo US approval Significantly reduced healthcare costs and resource use • Phesgo (PH FDC SC) achieves equivalent serum concentrations as IV at cycle 7 in neoadjuvant HER2+ eBC • 85% of patients prefer Phesgo compared to standard IV administration • US approval achieved in June; fi
Slide 26: HR+/HER2- franchise: Potentially best in class SERD
HR+/HER2- franchise: Potentially best in class SERD (RG6171) Strong efficacy as a single agent or in combination Selective ER degrader (SERD) Ph Ib results: Tumor responses RG6171 +/- palbociclib • 3rd generation oral SERD • Well-tolerated; strong efficacy as single agent or in combination in pre-tr
Slide 27: Hematology franchise: Growth from Venclexta, Gazyva and Polivy
Hematology franchise: Growth from Venclexta, Gazyva and Polivy CHFm YoY CER growth Hematology franchise Q2 update 2,000 CD20 franchise +3% • MabThera/Rituxan (-32%): Biosimilar erosion in US as expected -11% and market contraction due to COVID-19 1,500 -6% • Gazyva (+23%): Growth driven by 1L CLL (C
Slide 28: Hematology franchise: CD20 x CD3 program in NHL progresses
Hematology franchise: CD20 x CD3 program in NHL progresses Improving the standard of care in DLBCL and FL Glofitamab in R/R DLBCL Mosunetuzumab in R/R FL Tumor responses in 2/3L+ DLBCL Tumor responses in 3L+ FL • The ≥10mg cohorts in R/R DLBCL showed an ORR of 49.4% and a • Pooled data from 2.8mg to
Slide 29: Tecentriq overview: Growth driven by first-in-class indications
Tecentriq overview: Growth driven by first-in-class indications 1L HCC approved in the US; filed in EU/China Tecentriq Q2 update CHFm YoY CER growth Lung franchise (NSCLC, SCLC) • US/EU/Japan: Growth driven by 1L SCLC and 1L NSCLC 800 • US: Approval in 1L PDL1+ NSCLC achieved 700 +99% +54% +136% • C
Slide 30: Lung franchise: Tiragolumab + Tecentriq in 1L NSCLC
Lung franchise: Tiragolumab + Tecentriq in 1L NSCLC Meaningful efficacy improvement and excellent safety Anti-TIGIT antibody (tiragolumab) Randomized Ph II (CITYSCAPE): Tiragolumab + Tecentriq in 1L NSCLC ORR PFS: PD-L1 TPS ≥ 50% • Fully human IgG1/kappa Ab with • Tira + Tec showed clinically meanin
Slide 31: Immunology franchise: Overall stable sales
Immunology franchise: Overall stable sales CHFm YoY CER growth Immunology Q2 update 2,500 +7% Esbriet (+2%) +7% +2% • Growth in mild/moderate segments; remains EU market leader 2,000 +8% Actemra (+40%) 1,500 • Sales positively impacted by COVID-19 Xolair (+1%) 1,000 • Remains leader in biologics ast
Slide 32: Neuroscience franchise: Ocrevus in MS
Neuroscience franchise: Ocrevus in MS Market leadership in US continues with 21% total patient share1 CHFm YoY CER growth Ocrevus Q2 update 1,250 • COVID-19 impact in April/May due to reduced new patient +55% +38% starts and delayed dosing for existing patients +48% +12% 1,000 +59% • Strong recovery
Slide 33: Neuroscience franchise: Risdiplam in type 1/2/3 SMA
Neuroscience franchise: Risdiplam in type 1/2/3 SMA Compelling benefit/risk profile in infants, children, and adults SMN2 splicing modifier FIREFISH part 2 results in type 1 SMA confirm highly competitive profile • Proven efficacy in infants, children, and adults • Durably increases SMN protein thro
Slide 34: Hemophilia A franchise
Hemophilia A franchise Hemlibra with 23% total US patient share after 33 months CHFm YoY CER growth Hemophilia Q2 update 600 +146% • US: Gaining market share in non-inhibitors; patients on 550 500 +59% treatment stay on treatment, COVID-19 impact due to +313% 450 postponed new patient starts >500% 4
Slide 35: Ophthalmology franchise: Building a global PDS platform
Ophthalmology franchise: Building a global PDS platform Positive Ph III results in nAMD to be discussed at ASRS Port Delivery System (PDS) Phase III (ARCHWAY) results in nAMD: Mean BCVA Change From Baseline • Refillable intraocular implant using proprietary needle assembly and customized formulation
Slide 36: New products account for ~40% of Pharma sales
New products account for ~40% of Pharma sales* 4 NME approvals in 2020: ENSPRYNG and PHESGO approved in Q2 CHFm % of Pharma Sales* 5,000 4,500 39% 4,000 29% 3,500 3,000 2,500 21% 2,000 15% 1,500 1,000 500 0 ** Q2 17 Q2 18 Q2 19 Q2 20 Erivedge Perjeta Kadcyla Gazyva Esbriet Cotellic Alecensa Tecentri
Slide 37: Roche Pharma Day 2020
Roche Pharma Day 2020 Strategic business outlook and late stage pipeline update Virtual Roche Pharma Day 2020 Senior management presenting: • Bill Anderson, CEO Pharma • Teresa Graham, Head of Global Product Strategy Monday, 14 September 2020 • Levi Garraway, Chief Medical Officer and Head Global Pr
Slide 38: 2020: Key late-stage news flow
2020: Key late-stage news flow* Virtual IR Event ASRS Roche Pharma Day Monday, 27 July Monday, 14 September 4:30pm-5:30pm CEST 2pm-5pm CEST * Outcome studies are event-driven: timelines may change 38
Slide 39: Diagnostics Division
Diagnostics Division Thomas Schinecker CEO Roche Diagnostics
Slide 40: Diagnostics Division sales
HY 2020: Diagnostics Division sales Growth driven by Molecular Diagnostics offsetting decline in routine testing due to COVID-19 HY 2020 HY 2019 Change in % CHFm CHFm CHF CER Diagnostics Division 6,079 6,275 -3 3 Centralised and Point of Care Solutions 3,181 3,762 -15 -10 Molecular Diagnostics 1,558
Slide 41: Diagnostics Division regional sales
HY 2020: Diagnostics Division regional sales Growth driven by North America and EMEA Japan North America +1% +13% EMEA1 ~4% of divisional sales ~29% of divisional sales +5% ~40% of divisional sales Asia Pacific Latin America -9% +6% ~22% of divisional sales ~6% of divisional sales 1 Europe, Middle E
Slide 42: Diagnostics Division highlights
HY 2020: Diagnostics Division highlights Growth driven by Molecular Diagnostics YoY CER growth Centralised and Point of Care -10% • Immunodiagnostics (-12%) Solutions • Clinical Chemistry (-14%) • Virology (+115%) Molecular 1 +61% • LightMix Systems (+171%) Diagnostics • POC MDx (+56%) Diabetes • Bl
Slide 43: Diagnostic Division Core operating profit growing at +9%
HY 2020: Diagnostic Division Core operating profit growing at +9% 2020 CER growth CHFm abs. CER vs PY Sales 6,079 +213 3% Royalties & other op. inc. 27 -5 -14% Cost of sales -2,904 -138 5% M&D -1,249 +80 -6% R&D -710 -49 7% G&A -221 -9 4% Core operating profit 1,022 +95 9% Core OP in % of sales 16.8
Slide 44: SARS-CoV-2 diagnostics portfolio
SARS-CoV-2 diagnostics portfolio Comprehensive portfolio launched in record time Clinical Labs Point of Care Molecular • cobas® SARS-CoV-2 solutions • TIB MOLBIOL LightMix® Modular SARS-CoV-2 • cobas® SARS-CoV-2 & In development Influenza A/B • cobas® Flu A, Flu B and SARS-CoV-2 In development Serol
Slide 45: Elecsys SARS-CoV-2 serology solutions
Elecsys® SARS-CoV-2 serology solutions Broadening the portfolio for SARS-CoV-2 antibody testing Elecsys® Anti-SARS-CoV-2 Elecsys® In-solution double-antigen sandwich • Immunoassay detecting antibodies to nucleocapsid protein (anti-N) • Excellent performance confirmed in internal as well as external
Slide 46: Global launch of cobas prime Pre-analytical System
Global launch of cobas® prime Pre-analytical System* Accelerating speed and efficiency in the molecular lab • First-of-its-kind solution for multiple sample types cobas® prime cobas® 6800 • End-to-end automation for testing consolidation • Reduces manual steps in molecular labs by 86%** • Reduces ma
Slide 47: PD-L1 (SP263) and HER2 Dual ISH digital pathology algorithms
PD-L1 (SP263) and HER2 Dual ISH digital pathology algorithms* Improving the speed and accuracy of cancer diagnosis SCANNING PATHOLOGIST IMAGE WORKFLOW ANALYSIS VENTANA DP 200 NAVIFY Digital uPath Image Analysis Pathology Algorithms • The first next generation CE-IVD algorithms utilizing whole slide
Slide 48: Key launches 2020
Key launches 2020 Area Product Description Market1 Instruments/ Workflow cobas® prime Next generation pre-analytical platform to support cobas® 6800/8800 Systems CE Devices Diabetes Care Accu-Chek Solo Diabetes Manager Integration of the Accu-Chek Guide test strip technology into the Accu-Chek Solo
Slide 49: Finance
Finance Alan Hippe Chief Financial Officer
Slide 50: HY 2020 results, Focus on Cash, Outlook
HY 2020 results Focus on Cash Outlook 50
Slide 51: HY 2020: Highlights
HY 2020: Highlights Business • Sales growth of +1%1 and Core operating profit up +2%1 • Core EPS growth +2%1 Cash flow • Operating Free Cash Flow of CHF 5.0bn, -26%1 lower due to higher net working capital and higher investments in intangible assets • Net debt slightly up by CHF 0.4bn vs. Jun 30th 2
Slide 52: HY 2020: Group sales - May heavily impacted by COVID-19
HY 2020: Group sales - May heavily impacted by COVID-19 Recovery started in June Pharmaceuticals • Impact in May driven by patients delaying appointments (mainly but not only chronic diseases) • Recovery in the last weeks of the quarter Diagnostics • Impact in April/May driven by decline in routine
Slide 53: HY 2020: Group performance
HY 2020: Group performance Sales up by +1% and Core EPS up by +2% HY 2020 HY 2019 Change in % CHFm CHFm CHF CER Sales 29,281 30,469 -4 1 Core operating profit 11,766 12,363 -5 2 as % of sales 40.2 40.6 Core net income 9,443 9,896 -5 3 as % of sales 32.2 32.5 Core EPS (CHF) 10.44 11.12 -6 2 IFRS net
Slide 54: HY 2020: Core EPS development
HY 2020: Core EPS development Operations growth is driver for Core EPS growth, more than compensating lower gains on product disposals CHF +1.9% +1.3 p +3.6 p -2.6 p -0.2 p -0.2 p 10.98 11.18 H1 2019 Gains product Gains ROOI Gains Gains equityequity securities Resolution Resolution tax tax disputes
Slide 55: HY 2020: Group operating performance
HY 2020: Group operating performance Core operating profit growth ahead of sales growth 2020 CER growth CHFm abs. CER vs PY Sales 29,281 +406 1% Royalties & other op. inc. 1,097 -154 -12% Cost of sales -7,079 +484 -6% M&D -4,515 +73 -2% R&D -5,787 -407 7% G&A -1,231 -123 11% Core operating profit 11
Slide 56: Royalties and other operating income
HY 2020: Royalties and other operating income Decline driven by lower income from product disposals CHFm +47 +42 +107 -75 1,282 -306 Royalties and other operating income decreased by -12% at CER 1,097 Royalty income Out-licensing Other operating Gains/losses HY 2019 Cabilly others income income disp
Slide 57: Core OP and margin maintained at high levels
HY 2020: Core OP and margin maintained at high levels % of sales 47.2% 47.5% 47.2% 39.7% 40.6% 40.2% +0.5%p¹ +0.4%p¹ +2%¹ +2%¹ 17.1% 17.0% 16.8% CHFm 12,363 11,766 11,500 11,162 10,961 +0.9%p¹ 10,301 +9%¹ 1,074 1,064 1,022 2018 2019 2020 Roche Group Pharma Division Diagnostics Division 1 At CER=Cons
Slide 58: Core net financial result
HY 2020: Core net financial result Improvement driven by lower interest expenses CHFm • Net financial result improved by +3% at CER • Interest expenses1 decreased by +30% at CER -476 -451 +104 +15 -23 -26 -45 HY 2019 Equity Net interest Interest All other, HY 2020 FX G/L securities income expenses1
Slide 59: Group Core tax rate
HY 2020: Group Core tax rate Stable tax rate with similar impacts from resolution of tax disputes in HY 2020 and HY 2019 Figures in % -0.2 16.7 16.5 HY 2019 Decrease in HY 2020 Core tax rate 59
Slide 60: Non-core items
HY 2020: Non-core items Non-core operating expenses lower than in 2019 driven by the Accutane provision release 2019 2020 Change in % CHFbn CHFbn CHFbn CHF CER Core operating profit 12.4 11.8 -0.6 -5 +2 Global restructuring plans -0.5 -0.3 +0.2 Amortisation of intangible assets -0.7 -0.8 -0.1 1 Impa
Slide 61: HY 2020 results, Focus on Cash, Outlook
HY 2020 results Focus on Cash Outlook 61
Slide 62: Operating free cash flow and margin
HY 2020: Operating free cash flow and margin 36.2% 33.9% % of sales 28.6% 24.6% 23.5% 17.2% -9.6%p¹ -6.7%p¹ 6.8% -0.7% -6.1% CHFm 8,042 7,900 8,191 7,508 +6.6%p¹ -28%¹ -26%¹ 5,454 5,036 429 2018 2019 2020 -¹ 2019 -44 -380 Roche Group Pharma Division Diagnostics Division 1 At CER=Constant Exchange Ra
Slide 63: Operating free cash flow
HY 2020: Operating free cash flow Lower than PY (-26%) driven by higher NWC and higher IA investments CHFm -657 -1,094 -111 -610 7,508 OFCF decreased by -26% / -1,949m at CER 5,036 OP net of Inv. in Inv. in HY 2019 cash adjust. NWC HY 2020 PP&E1 IA CER=Constant Exchange Rates; OP=operating profit; N
Slide 64: Group net debt up vs. YE 2019
HY 2020: Group net debt up vs. YE 2019 Driven by dividends paid Free Cash Flow CHF 3.3bn CHFbn vs. 5.3bn in 2019 -1.7 +5.0 -2.5 [HY19: +7.5] -9.6 -8.8 [HY19: -8.4] Taxes -1.2 Dividends paid -7.8 Treasury -0.5 M&A & Alli. trans. -0.7 Trans. own eq. instr. -1.4 Curr. Transl. & Other +0.3 Operating Div
Slide 65: Balance sheet 30 June 2020
Balance sheet 30 June 2020 Equity ratio at 43% (30 June 2019: 39%; 31 Dec 2019 43%) % change in CER % change in CER CHFbn vs 31 Dec 2019 vs 31 Dec 2019 83.1 -1% 83.1 -1% Cash and 80.4 80.4 marketable 11.9 6.3 -46% 24.1 22.5 securities 14% 8% Current -5% 29% 28% 19.4 21.4 +14% liabilities Other 23% 2
Slide 66: HY 2020 results, Focus on Cash, Outlook
HY 2020 results Focus on Cash Outlook 66
Slide 67: High currency impact expected in 2020
High currency impact expected in 2020 CHF / USD Average -3% -3% -3% -4% YTD 2019 1.00 1.00 0.99 1.00 Assuming the 30 June 2020 exchange rates remain stable until end of 2020, 0.97 0.97 0.96 0.96 2020 impact 1 is expected to be (%p): Assumed average YTD 2020 Q1 HY Sep FY 0.97 0.97 0.96 0.97 0.97 0.95
Slide 68: 2020 outlook confirmed
2020 outlook confirmed Further growing top and bottom line Group sales growth1 • Low- to mid-single digit Core EPS growth1 • Broadly in line with sales growth Dividend outlook • Further increase dividend in Swiss francs 1 At Constant Exchange Rates (CER); based on the current assessment of the COVID
Slide 69: Changes to the development pipeline
Changes to the development pipeline Q2 2020 update New to phase I New to phase II New to phase III New to registration 5 NMEs: 3 NMEs: (transitioned from phase I) 1 AI: 2 AIs: RG6279 PD1-IL2v - solid tumors RG7774 NME - retinal disease RG1569 Actemra+remdesivir - COVID-19 RG7421 Cotellic+Zelboraf+Te
Slide 70: Roche Group development pipeline
Roche Group development pipeline Phase I (43 NMEs + 14 AIs) Phase II (20 NMEs + 12 AIs) RG6026 glofitamab / combos heme tumors RG7769 PD1 x TIM3 solid tumors RG6180 iNeST* + pembrolizumab malignant melanoma RG6058 tiragolumab combos heme & solid tumors RG7802 cibisatamab ± T solid tumors RG6357 SPK-
Slide 71: Roche Group development pipeline
Roche Group development pipeline Phase III (8 NMEs + 30 AIs) Registration (5 NMEs + 11 AIs) RG6013 Hemlibra mild to moderate hemophilia A RG7446/ Tecentriq bTMB-high RG6264 Phesgo 1 Perjeta + Herceptin FDC SC HER2+ BC 1L NSCLC tiragolumab + T + chemo 1L SCLC RG6268 or entrectinib ROS1+ Rozlytrek (en
Slide 72: NME submissions and their additional indications
NME submissions and their additional indications Projects in phase II and III Port Delivery System RG6321 with ranibizumab wAMD tiragolumab + rh pentraxin-2 etrolizumab RG7413 RG6058 Tecentriq RG6354 PRM-151 ulcerative colitis 1L PD-L1+ cervical ca IPF Xofluza ✓ tiragolumab + TLR7 ago (3) rh pentrax
Slide 73: AI submissions for existing products
AI submissions for existing products Projects in phase II and III New Molecular Entity (NME) Immunology Neuroscience Actemra Additional Indication (AI) Infectious Diseases Ophthalmology RG1569 Oncology / Hematology CardioMetabolism Other COVID-19 pneumonia Actemra + remdesivir RG1569 COVID-19 pneumo
Slide 74: Major pending approvals 2020
Major pending approvals 2020 US EU China Japan-Chugai satralizumab Rozlytrek (entrectinib) CellCept Kadcyla RG6168 NMOSD RG6268 ROS1+ NSCLC RG99 lupus nephritis RG3502 HER2+ eBC adj Filed Aug 2019 Filed Jan 2019 Filed Aug 2018 Filed Aug 2019 Xolair Rozlytrek (entrectinib) Avastin Tecentriq +Avastin
Slide 75: Major granted approvals 2020
Major granted approvals 2020 US EU China Japan-Chugai Venclexta+Gazyva Polivy Kadcyla Rozlytrek (entrectinib) RG7601 1L CLL RG7596 r/r DLBCL RG3502 HER2+ eBC RG6268 ROS1+ NSCLC Mar 2020 January 2020 Jan 2020 Feb 2020 Tecentriq + Avastin Venclexta+Gazyva Tecentriq + chemo Alecensa RG7446 1L HCC RG760
Slide 76: Doing now what patients need next
Doing now what patients need next